Skip to main content

Table 2 Smoking Abstinence Outcomes

From: Methylphenidate for treating tobacco dependence in non-attention deficit hyperactivity disorder smokers: A pilot randomized placebo-controlled trial

 

Placebo

(N = 40)

OROS-MPH

(N = 40)

 

Week

No. (%)

No. (%)

p†

Week 12 (end of medication)

   

   7-day point prevalence*

4 (10.0)

1 (2.5)

0.973

   Prolonged abstinence

4 (10.0)

1 (2.5)

0.973

Week 24

   

   7-day point prevalence*

3 (7.5)

4 (10.0)

0.500

   Prolonged abstinence

1 (2.5)

1 (2.5)

0.753

  1. * Biochemically confirmed by expired CO ≤ 8 ppm.
  2. † One-tailed Fisher's exact test comparing OROS-MPH vs placebo.
Back to article page

Journal of Negative Results in BioMedicine

ISSN: 1477-5751

Contact us